Level Up: Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to Severe Atopic Dermatitis: Results of an Open-label, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study

Key opinion leaders in the management of dermatological disorders assess the effectiveness of systemic therapies in patients undergoing treatment.

Atopic dermatitis experts evaluate the integration of composite scores and quality of life measures as a new benchmark for comprehensive disease management.

Medical experts examine the practical application of clinical study results to real-world atopic dermatitis management strategies.

Dermatology experts analyze the superior outcomes of upadacitinib compared with dupilumab across key efficacy measures in atopic dermatitis treatment.

Dermatology experts provide critical analysis and interpretation of data from clinical trials to inform evidence-based practice in the field.

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

Key opinion leaders examine upadacitinib's role in managing atopic dermatitis and its impact on improving patients' quality of life.

Christopher Bunick, MD, PhD, and Raj Chovatiya, MD, PhD, discuss results of an open-label phase 3b/4 study for atopic dermatitis.